Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib vs Lapatinib in HER2+ Metastatic Breast Cancer
NCT03080805Phase 3Unknown
- Sponsor
- Hengrui
- Start
- May 2017
- Primary completion
- Mar 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of pyrotinib in HER2-positive metastatic breast cancer, sponsored by Hengrui. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT03080805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03080805.